Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
28.10
+0.67 (2.44%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Zymeworks Revenue
In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth. Zymeworks had revenue of $2.52M in the quarter ending December 31, 2025, a decrease of -91.90%.
Revenue (ttm)
$105.97M
Revenue Growth
+38.87%
P/S Ratio
19.56
Revenue / Employee
$401,383
Employees
264
Market Cap
2.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| Stoke Therapeutics | 184.42M |
| Day One Biopharmaceuticals | 158.18M |
| Ascentage Pharma Group International | 82.08M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 51.95M |
ZYME News
- 5 days ago - Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - GlobeNewsWire
- 5 days ago - Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference - Transcripts
- 9 days ago - Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform - GlobeNewsWire
- 10 days ago - Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 - GlobeNewsWire
- 11 days ago - Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 17 days ago - Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - GlobeNewsWire
- 25 days ago - Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewsWire
- 27 days ago - Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewsWire